Perrigo Company plc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $4.1B-5.2% YoYTTM through 27 Jun 2026
Net Income -$1.7BTTM through 27 Jun 2026
Free Cash Flow $119.3MTTM through 27 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 35.1% |
| EBITDA Margin | -29.3% |
| Operating Margin | -26.4% |
| Net Margin | -41.9% |
Returns
-48.0%ROE
-16.4%ROA
Balance Sheet Health
Debt / Equity1.24x
Current Ratio2.32x
Net Debt$3.1B
Cash & Equivalents$432.1M
Quality Metrics
Altman Z-Score-0.42
Piotroski F-Score3 / 9
FCF Margin2.9%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $4.3B
Diluted EPS-$12.52TTMFY2025: $-10.29
Dividend
$0.58Per share, FY20264.05%Yield-9.6%5-yr growth
Capital Allocation
R&D Spend$95.1M
Capex Intensity1.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Consumer Self-Care Americas (CSCA) | $2.6B | -4.0% | View detailsUndergoing strategic review for Infant Formula and Oral Care businesses. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.